The Japan Multiple Sclerosis Drugs Market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Extensive research and development activity in multiple sclerosis treatment, increasing prevalence of multiple sclerosis and growing need for better multiple sclerosis treatment options are the major drivers which will propel the demand for MS drugs in the forecast period. The rapid spread of the COVID-19 pandemic has increased concerns surrounding the use of disease-modifying therapies (DMT) that are increasingly prescribed for MS and expected to increase the patient’s risk for coronavirus infection.
The rising number of patients, increased screening rates and the need for better care options are some of the key factors for the multiple sclerosis treatment market growth in the coming years. In an ageing population, the disease is more prone, hence the surge in the geriatric population further escalates the multiple sclerosis treatment market growth. Many pharmaceutical companies are conducting clinical studies for the development of innovative therapies for MS.